Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.

被引：0
|
作者：
Tang, Lin-Quan
Jia, Guo-Dong
Lv, Xiao-Fei
Xie, Siyi
Chen, Yu
Li, Ji-Bin
Li, Xiao Yun
Zhu, Manyi
Liu, Sai Lan
Liu, LiTing
Sun, Xue-Song
Guo, Shanshan
Luo, Dong-Hua
Chen, Qiu-Yan
Mai, Hai-Qiang
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Clin Res, Ctr Canc, State Key Lab Oncol South China,Collaborative Inn, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Ctr Canc, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6042
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
    Peng, Linhui
    Chen, Tao
    Chen, Yajin
    Xu Yunxiuxiu
    Wang, Jie
    Zhong, Guoping
    Xiao, Zhiyu
    Zhou, Zhenyu
    Ye, Congting
    Li, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [43] Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
    Guo, Ye
    Li, Zhendong
    Chen, Wantao
    Fang, Meiyu
    Liu, Zhigang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
    Ding, X.
    Zhang, W.
    You, R.
    Zou, X.
    Wang, Z.
    Ouyang, Y-F.
    Liu, Y-L.
    Peng, L.
    You-Ping, L.
    Duan, C-Y.
    Yang, Q.
    Lin, C.
    Yulong, X.
    Chen, S-Y.
    Gu, C-M.
    Huang, P. Y.
    Hua, Y.
    Chen, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S846 - S846
  • [45] An open-label, placebo-controlled, randomized phase II trial of camrelizumab combined with or without apatinib or capecitabine in the treatment of previously treated advanced pancreatic cancer
    Chen, Jianhua
    Liu, Jun
    Li, Ning
    Huang, Weiyi
    Chen, Donghui
    Tao, Wei
    Wang, Hongxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Varadarajan, Prakash
    Kotsakis, Athanasios Panayotis
    Martin, Daniel
    Gutkind, Jorge Silvio
    Gibson, Michael K.
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial
    Liang, Hu
    Jiang, Yao-Fei
    Liu, Guo-Ying
    Wang, Lin
    Wang, Jian-Wei
    Lu, Nian
    Xia, Wei-Xiong
    Ke, Liang-Ru
    Ye, Yan-Fang
    Duan, Jin-Lin
    Bei, Wei-Xin
    Dong, Shu-Hui
    Li, Wang-Zhong
    Liu, Li-Ting
    Zhao, Chong
    Xie, Changqing
    Xiang, Yan-Qun
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [48] Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial
    Hu Liang
    Yao-Fei Jiang
    Guo-Ying Liu
    Lin Wang
    Jian-Wei Wang
    Nian Lu
    Wei-Xiong Xia
    Liang-Ru Ke
    Yan-Fang Ye
    Jin-Lin Duan
    Wei-Xin Bei
    Shu-Hui Dong
    Wang-Zhong Li
    Li-Ting Liu
    Chong Zhao
    Changqing Xie
    Yan-Qun Xiang
    Nature Communications, 15
  • [49] Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.
    Shen, Lin
    Peng, Zhi
    Zhang, Yan-Qiao
    Wei, Jia
    Wang, Feng
    Ying, Jieer
    Deng, Yanhong
    Gu, Kangsheng
    Cheng, Ying
    Yuan, Xianglin
    Xiao, Juxiang
    Wang, Linna
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
    Liao, Zhichao
    Li, Feng
    Zhang, Chao
    Zhu, Lei
    Shi, Yehui
    Zhao, Gang
    Bai, Xu
    Hassan, Shafat
    Liu, Xinyue
    Li, Ting
    Xing, Peipei
    Zhao, Jun
    Zhang, Jin
    Xing, Ruwei
    Teng, Sheng
    Yang, Yun
    Chen, Kexin
    Yang, Jilong
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2019, 51 (3): : 1 - 11
12345